Acromegaly: A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)Human Growth Hormone: A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.Growth Hormone-Secreting Pituitary Adenoma: A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.Octreotide: A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.Somatostatin: A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.Gigantism: The condition of accelerated and excessive GROWTH in children or adolescents who are exposed to excess HUMAN GROWTH HORMONE before the closure of EPIPHYSES. It is usually caused by somatotroph hyperplasia or a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.Insulin-Like Growth Factor I: A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor.Growth Hormone: A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.Adenoma: A benign epithelial tumor with a glandular organization.Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.Adenoma, Acidophil: A benign tumor, usually found in the anterior lobe of the pituitary gland, whose cells stain with acid dyes. Such pituitary tumors may give rise to excessive secretion of growth hormone, resulting in gigantism or acromegaly. A specific type of acidophil adenoma may give rise to nonpuerperal galactorrhea. (Dorland, 27th ed)Growth Hormone-Releasing Hormone: A peptide of 44 amino acids in most species that stimulates the release and synthesis of GROWTH HORMONE. GHRF (or GRF) is synthesized by neurons in the ARCUATE NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, GHRF stimulates GH release by the SOMATOTROPHS in the PITUITARY GLAND.Thyrotropin-Releasing Hormone: A tripeptide that stimulates the release of THYROTROPIN and PROLACTIN. It is synthesized by the neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, TRH (was called TRF) stimulates the release of TSH and PRL from the ANTERIOR PITUITARY GLAND.Receptors, Somatotropin: Cell surface proteins that bind GROWTH HORMONE with high affinity and trigger intracellular changes influencing the behavior of cells. Activation of growth hormone receptors regulates amino acid transport through cell membranes, RNA translation to protein, DNA transcription, and protein and amino acid catabolism in many cell types. Many of these effects are mediated indirectly through stimulation of the release of somatomedins.Ergolines: A series of structurally-related alkaloids that contain the ergoline backbone structure.Peptides, Cyclic: Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).Adenoma, Chromophobe: A benign tumor of the anterior pituitary in which the cells do not stain with acidic or basic dyes.Prolactinoma: A pituitary adenoma which secretes PROLACTIN, leading to HYPERPROLACTINEMIA. Clinical manifestations include AMENORRHEA; GALACTORRHEA; IMPOTENCE; HEADACHE; visual disturbances; and CEREBROSPINAL FLUID RHINORRHEA.Hyperprolactinemia: Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)Pituitary Gland: A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM.Macroglossia: The presence of an excessively large tongue, which may be congenital or may develop as a result of a tumor or edema due to obstruction of lymphatic vessels, or it may occur in association with hyperpituitarism or acromegaly. It also may be associated with malocclusion because of pressure of the tongue on the teeth. (From Jablonski, Dictionary of Dentistry, 1992)Sphenoid Bone: An irregular unpaired bone situated at the SKULL BASE and wedged between the frontal, temporal, and occipital bones (FRONTAL BONE; TEMPORAL BONE; OCCIPITAL BONE). Sphenoid bone consists of a median body and three pairs of processes resembling a bat with spread wings. The body is hollowed out in its inferior to form two large cavities (SPHENOID SINUS).Hormones: Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.Hypercementosis: A regressive change of teeth characterized by excessive development of secondary cementum on the tooth surface. It may occur on any part of the root, but the apical two-thirds are most commonly affected. (Dorland, 27th ed)Fibrous Dysplasia, Polyostotic: FIBROUS DYSPLASIA OF BONE affecting several bones. When melanotic pigmentation (CAFE-AU-LAIT SPOTS) and multiple endocrine hyperfunction are additionally associated it is referred to as Albright syndrome.Glucose Tolerance Test: A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg).Hormone Antagonists: Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.Hypophysectomy: Surgical removal or destruction of the hypophysis, or pituitary gland. (Dorland, 28th ed)Endocrine Surgical Procedures: Surgery performed on any endocrine gland.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Meglutol: An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids. It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which is the rate limiting enzyme in the biosynthesis of cholesterol.Mastectomy, Extended Radical: Radical mastectomy with removal of the ipsilateral half of the sternum and a portion of ribs two through five with the underlying pleura and the internal mammary lymph nodes.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Radiotherapy, Conformal: Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.Product Surveillance, Postmarketing: Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.Computers, Mainframe: Large computers in both size and capacity.Clinical Trials, Phase IV as Topic: Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries.NewsNewspapers: Publications printed and distributed daily, weekly, or at some other regular and usually short interval, containing news, articles of opinion (as editorials and letters), features, advertising, and announcements of current interest. (Webster's 3d ed)Research: Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)Mass Media: Instruments or technological means of communication that reach large numbers of people with a common message: press, radio, television, etc.Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Rare Diseases: A large group of diseases which are characterized by a low prevalence in the population. They frequently are associated with problems in diagnosis and treatment.Phonocardiography: Graphic registration of the heart sounds picked up as vibrations and transformed by a piezoelectric crystal microphone into a varying electrical output according to the stresses imposed by the sound waves. The electrical output is amplified by a stethograph amplifier and recorded by a device incorporated into the electrocardiograph or by a multichannel recording machine.Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.Echocardiography: Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.Thallium Radioisotopes: Unstable isotopes of thallium that decay or disintegrate emitting radiation. Tl atoms with atomic weights 198-202, 204, and 206-210 are thallium radioisotopes.Hydrocortisone: The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.Medical Laboratory Science: The specialty related to the performance of techniques in clinical pathology such as those in hematology, microbiology, and other general clinical laboratory applications.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Neurosurgery restores late GH rise after glucose-induced suppression in cured acromegalics. (1/672)

OBJECTIVE AND DESIGN: A decrease of GH levels below 2 microg/l after an oral glucose tolerance test (OGTT) is still currently accepted as the gold standard for assessing cure in surgically treated acromegaly. Whether glucose-induced suppression of GH is accompanied by a restoration of normal GH late rebound has not yet been evaluated in this disease. In order to assess the restoration of normal GH regulation after removal of a pituitary adenoma, we have evaluated GH changes after an OGTT in a series of selected acromegalic patients (transsphenoidal surgery and lack of pituitary failure). METHODS: Twenty-nine patients (13 male, 16 female, age range 27-70 years) entered the study. Their neuroradiological imaging before neurosurgery showed microadenoma in 7, intrasellar macroadenoma in 8 and macroadenoma with extrasellar extension in 14. Plasma GH levels were assayed up to 300 min after glucose administration (75 g p.o.) and IGF-I on basal samples. RESULTS: Basal GH levels were below 5 microg/l in 20 patients and below 2 microg/l in 5 of these. Normal age-adjusted IGF-I levels were observed in 12 patients. GH values were suppressed below 2 microg/l during an OGTT in 13 patients, and below 1 microg/l in 7 of these. In 9 patients out of these 13, a marked rise in GH levels occurred after nadir. Baseline and nadir GH values of these 9 patients were not different from the corresponding values of the other 4 patients without OGTT-induced late GH peaks. CONCLUSIONS: GH rebound after GH nadir occurs in acromegalic patients considered as cured on the basis of OGTT-induced GH suppression and/or IGF-I normalization. The restoration of this physiological response could be regarded as a marker of recovered/preserved integrity of the hypothalamic-pituitary axis. Even though the reason for this GH rebound has not yet been elucidated (GHRH discharge?/end of somatostatin inhibition?), the lack of late GH peak in the patients regarded as cured by the usual criteria could be due to injury to the pituitary stalk caused by the adenoma or by surgical manipulation.  (+info)

Kleine-Levin and Munchausen syndromes in a patient with recurrent acromegaly. (2/672)

Hypothalamic disease often affects the patients' personality and this also applies to pituitary tumors with suprasellar extension. We report on a patient with a 12-year history of recurrent acromegaly, treated with three transphenoidal operations, single field radiation therapy and bromocriptine/octreotide administration. During the course of follow-up she presented with self-inflicted anemia and Kleine-Levin syndrome (hypersomnia, hyperphagia and hypersexuality). Furthermore, she developed post-radiation necrosis within the right temporal lobe. Whether her neurological and personality disorders result - at least partially - from the acromegaly or the temporal lobe necrosis remains unclear.  (+info)

Growth in Sotos syndrome. (3/672)

Although there are several reports on infant and childhood growth in patients with Sotos syndrome, there is little information on the final height achieved and puberty. Growth data on 40 patients (20 female and 20 male) aged 2-31 years were collected. These showed that patients with Sotos syndrome are excessively tall at birth, during infancy, and during childhood. Disproportionately long limbs constitute much of the increase in stature. However, the combination of advanced bone age and early onset of menarche led to a mean (SD) final height of 172.9 (5.7) cm in women. This is within the normal range for the population. Most of the men also attained a final height (mean, 184.3 cm; SD, 6.0) within the normal range, although exceptions were more likely in men than in women. Therefore, these results show that most patients with Sotos syndrome do not require intervention to limit their adult height.  (+info)

Cell death in acromegalic cardiomyopathy. (4/672)

BACKGROUND: Prolonged untreated acromegaly leads to a nonspecific myopathy characterized by ventricular dysfunction and failure. However, the mechanisms responsible for the alterations of cardiac pump function remain to be defined. Because cell death is implicated in most cardiac disease processes, the possibility has been raised that myocyte apoptosis may occur in the acromegalic heart, contributing to the deterioration of ventricular hemodynamics. METHODS AND RESULTS: Ten acromegalic patients with diastolic dysfunction and 4 also with systolic dysfunction were subjected to electrocardiography, Holter monitoring, 2-dimensional echocardiography, cardiac catheterization, and biventricular and coronary angiography before surgical removal of a growth hormone-secreting pituitary adenoma. Endomyocardial biopsies were obtained and analyzed quantitatively in terms of tissue scarring and myocyte and nonmyocyte apoptosis. Myocardial samples from papillary muscles of patients who underwent valve replacement for mitral stenosis were used for comparison. The presence of apoptosis in myocytes and interstitial cells was determined by confocal microscopy with the use of 2 histochemical methods, consisting of terminal deoxynucleotidyl transferase (TdT) assay and Taq probe in situ ligation. Acromegaly was characterized by a 495-fold and 305-fold increase in apoptosis of myocytes and nonmyocytes, respectively. The magnitude of myocyte apoptosis correlated with the extent of impairment in ejection fraction and the duration of the disease. A similar correlation was found with the magnitude of collagen accumulation, indicative of previous myocyte necrosis. Myocyte death was independent from the hormonal levels of growth hormone and insulin-like growth factor-1. Apoptosis of interstitial cells did not correlate with ejection fraction. CONCLUSIONS: Myocyte cell death, apoptotic and necrotic in nature, may be critical for the development of ventricular dysfunction and its progression to cardiac failure with acromegaly.  (+info)

Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. (5/672)

BACKGROUND: Treatment of acromegaly with octreotide increases the proportion of deoxycholic acid in, and the cholesterol saturation of, bile and induces the formation of gallstones. Prolongation of intestinal transit has been proposed as the mechanism for the increase in the proportion of deoxycholic acid in bile. AIMS: To study the effects of octreotide on intestinal transit in acromegalic patients during octreotide treatment, and to examine the relation between intestinal transit and bile acid composition in fasting serum. METHODS: Mouth to caecum and large bowel transit times, and the proportion of deoxycholic acid in fasting serum were measured in non-acromegalic controls, acromegalic patients untreated with octreotide, acromegalics on long term octreotide, and patients with simple constipation. Intestinal transit and the proportion of deoxycholic acid were compared in acromegalic patients before and during octreotide. RESULTS: Acromegalics untreated with octreotide had longer mouth to caecum and large bowel transit times than controls. Intestinal transit was further prolonged by chronic octreotide treatment. There were significant linear relations between large bowel transit time and the proportion of deoxycholic acid in the total, conjugated, and unconjugated fractions of fasting serum. CONCLUSIONS: These data support the hypothesis that, by prolonging large bowel transit, octreotide increases the proportion of deoxycholic acid in fasting serum (and, by implication, in bile) and thereby the risk of gallstone formation.  (+info)

Pituitary tumours in the elderly: a 20 year experience. (6/672)

The proportion of the elderly in the population is increasing, and the appreciation and management of medical problems in this age group will therefore become more important. We therefore decided to determine the clinical features and types of pituitary tumour presenting in the elderly, and to examine the treatment and outcome in this group. We conducted a retrospective case-note review from a specialist endocrine and neurosurgical unit in a tertiary referral centre. Eighty-four patients aged 65 years and over on diagnosis of a pituitary tumour were referred to the unit between 1975 and 1996. There were 45 males and 39 females, and the mean age was 72.4 years (range 65-86). Over half of the pituitary lesions were non-functioning adenomas (NFAs) (60.7%). GH-secreting tumours were present in 11 (13.1%) and macroprolactinomas in 7 (8.1%). Four patients had microadenomas and 17 had miscellaneous pituitary-related lesions. Visual deterioration was the commonest mode of presentation in 33 (39.3%), but 54 (64.3%) had evidence of visual impairment on detailed examination. Despite the majority of patients (80.8%) having coexisting medical conditions, trans-sphenoidal surgery was performed in 60 (71.4%) and was well tolerated with a zero peri- and post-operative mortality rate, and post-operative complications in 11 (13.1%). Pituitary tumours in the elderly are most frequently NFAs that present with visual deterioration and hypopituitarism. The fact that 46.5% were pan-hypopituitary on diagnosis and that 64.3% of patients had visual impairment suggests a delay in diagnosis in this age group. Despite significant coexisting medical pathology in this large series of patients, surgery was safe and successful in the majority.  (+info)

Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects. (7/672)

OBJECTIVE: To study the effect of octreotide on glucagon-like peptide (7-36) amide (GLP-1) and insulin secretion in patients with pituitary tumors during preoperative treatment and in healthy subjects. DESIGN: Open design prospective clinical study. METHODS: Eighteen patients with pituitary macroadenomas (13 clinically nonfunctioning (NFA; 11/13 had GH insufficiency), 5 GH secreting (GHA)) received preoperative octreotide treatment: 3x100 microg/day s. c. for 3 months, and 3x500 microg/day s.c. for an additional 3 months. Seven healthy subjects received (for ethical reasons) only 3x100 microg/day for 10 days. A standardized meal (St-M) test, oral glucose test (oGTT) and i.v. glucose test (ivGTT) were done before octreotide therapy, on days 1, 2 and 3 (D1,2,3), after 3 months (M3) and 6 months (M6) of octreotide treatment in the patients, and before treatment, on D1,2,3 and on D8,9,10 of octreotide treatment in the healthy subjects. Serum GLP-1, insulin and GH as well as plasma glucose were determined for 180 min (oGTT, St-M) or 120 min (ivGTT). RESULTS: Pretreatment fasting GLP-1 concentrations as well as integrated responses (area under the curve 0-180 min) to oGTT and St-M were not significantly different between NFA, GHA and healthy subjects. During the oGTT, octreotide initially almost abolished the early (0-60 min) and diminished the late (60-180 min) GLP-1 and insulin responses in patients and healthy subjects. At M6 integrated insulin responses had significantly recovered, while the increase in GLP-1 response failed to reach significance (GLP-1: 56.5% of pretreatment at D2 versus 93.5% at M6 and 41.2 versus 63.1% in NFA and GHA respectively; insulin: 50.2 versus 71.2% and 35.5 versus 70. 4%). An escape of GLP-1 and insulin in healthy subjects (D2 versus D9) was not significant. Intestinal glucose absorption was apparently not reduced, since the early glucose rise was similar before and during octreotide treatment. During the St-M the GLP-1 and insulin responses were similarly suppressed by octreotide and recovered during ongoing treatment (GLP-1: 49.6% of pretreatment at D1 versus 79.0% at M6 in NFA and 46.9 versus 52.9% in GHA. Insulin: 27.6 versus 83.9% and 23.5 versus 54.4%). The escape was significant in NFA but not in GHA. In the healthy subjects the escape was already significant on D8 (GLP-1: 39.5% of pretreatment at D1 versus 68.3% at D8; insulin: 36.6 versus 53.8%). During the ivGTT GLP-1 did not increase. The early insulin response (0-30 min) was abolished by octreotide, followed by a reduced peak at 60 min. The reduction of the integrated insulin response during ivGTT was similar to that during oGTT. An insulin escape reached significance only for NFA (52. 6% of pretreatment at D3 versus 66.7% at M6). Glucose tolerance (KG value) deteriorated and did not improve during ongoing treatment. Octreotide suppressed the median GH concentration (8h profile) of the GHA patients from 10.3 microg/l (pretreatment) to 5.8, 6.3 and 3. 7 microg/l at D4, M3 and M6 with no escape. GH was 1.5 microg/l postoperatively. CONCLUSIONS: Octreotide abolishes the early and diminishes the late GLP-1 and insulin responses to oGTT and St-M in NFA and GHA patients and in healthy subjects. In contrast to GH, both hormones partially escape from suppression during ongoing therapy. During treatment with our conventional octreotide doses suppression of insulin secretion is maximal. Under these conditions an effect of the additional loss of GLP-1 is not apparent. Basal GLP-1 concentrations and integrated responses to oGTT and St-M were similar in healthy subjects and in patients with GH excess or GH insufficiency.  (+info)

A case of acromegaly accompanied by adrenal preclinical Cushing's syndrome. (8/672)

We encountered a 58-year-old woman with acromegaly accompanied by a cortisol-secreting adrenal tumor without clinical features of hypercortisolism. The simultaneous occurrence of these two endocrinopathies in one individual is extremely rare. She was diagnosed as having diabetes mellitus 8 years ago. Afterwards, in spite of insulin therapy, her hyperglycemia could not be well controlled. Her acromegaly and preclinical Cushing's syndrome were histopathologically proven to be due to a pituitary adenoma and an adrenocortical adenoma, respectively. Successful treatment for these endocrinopathies resulted in greatly improved blood sugar control because of a reduction in insulin resistance. In this case of preclinical Cushing's syndrome, replacement therapy with glucocorticoid was able to be discontinued at only 8 weeks after adrenalectomy, so that the period of necessary replacement was much shorter than that for overt Cushing's syndrome. This is the first report describing insulin resistance before and after treatment in a case of acromegaly accompanied by adrenal preclinical Cushing's syndrome.  (+info)

Request for sample pages. Table of contents. 1. Report Introduction. 2. Acromegaly 2.1. Overview. 2.2. History 2.3. Acromegaly Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Acromegaly Diagnosis 2.6.1. Diagnostic Guidelines. 3. Acromegaly Current Treatment Patterns. 3.1. Acromegaly Treatment Guidelines. 4. Acromegaly - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends. 4.1.1.1. Assessment Summary. 4.1.2. Acromegaly Collaboration Deals. 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis. 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis. 4.1.2.3. Acromegaly Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment by Product Type (Mono / Combination). 5.1.2.1. Assessment by Stage and Product Type. 5.1.3. Assessment by Route of ...
Request for sample pages. Table of contents. 1. Report Introduction. 2. Acromegaly 2.1. Overview. 2.2. History 2.3. Acromegaly Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Acromegaly Diagnosis 2.6.1. Diagnostic Guidelines. 3. Acromegaly Current Treatment Patterns. 3.1. Acromegaly Treatment Guidelines. 4. Acromegaly - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends. 4.1.1.1. Assessment Summary. 4.1.2. Acromegaly Collaboration Deals. 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis. 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis. 4.1.2.3. Acromegaly Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment by Product Type (Mono / Combination). 5.1.2.1. Assessment by Stage and Product Type. 5.1.3. Assessment by Route of ...
Request for sample pages. Table of contents. 1. Report Introduction. 2. Acromegaly 2.1. Overview. 2.2. History 2.3. Acromegaly Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Acromegaly Diagnosis 2.6.1. Diagnostic Guidelines. 3. Acromegaly Current Treatment Patterns. 3.1. Acromegaly Treatment Guidelines. 4. Acromegaly - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends. 4.1.1.1. Assessment Summary. 4.1.2. Acromegaly Collaboration Deals. 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis. 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis. 4.1.2.3. Acromegaly Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment by Product Type (Mono / Combination). 5.1.2.1. Assessment by Stage and Product Type. 5.1.3. Assessment by Route of ...
Request for sample pages. Table of contents. 1. Report Introduction. 2. Acromegaly 2.1. Overview. 2.2. History 2.3. Acromegaly Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Acromegaly Diagnosis 2.6.1. Diagnostic Guidelines. 3. Acromegaly Current Treatment Patterns. 3.1. Acromegaly Treatment Guidelines. 4. Acromegaly - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends. 4.1.1.1. Assessment Summary. 4.1.2. Acromegaly Collaboration Deals. 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis. 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis. 4.1.2.3. Acromegaly Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment by Product Type (Mono / Combination). 5.1.2.1. Assessment by Stage and Product Type. 5.1.3. Assessment by Route of ...
increase in Turkish saddle sizes and destruction of its walls, which allows not only to establish the presence of a tumor and its size, but also to identify the data on tumor growth direction.Lack sella change does not exclude the presence of a small pituitary adenomas and acromegaly.The increase in Turkish saddle at Statistics Team of acromegaly is diagnosed in 80-93% of patients, including 145 patients - at 137, but only 68% according to other patients.. great diagnostic value also have other radiological signs of acromegaly, in particular changes in the spine.. Just as in the diagnosis of hormonally inactive pituitary tumors, the diagnosis of acromegaly is very important ophthalmologic research, especially the dynamic monitoring of changes in visual fields.Has revealed bitemporal hemianopsia half of patients with acromegaly.. biochemical and hormonal studies play a small role in the diagnosis of acromegaly.A known value in the diagnosis of acromegaly in the active phase is defined as the ...
acromegaly - MedHelps acromegaly Center for Information, Symptoms, Resources, Treatments and Tools for acromegaly. Find acromegaly information, treatments for acromegaly and acromegaly symptoms.
TY - JOUR. T1 - Plasma growth hormone response to thyrotropin releasing hormone in patients with active acromegaly. AU - Faglia, G.. AU - Beck-Peccoz, P.. AU - Ferrari, C.. AU - Travaglini, P.. AU - Ambrosi, B.. AU - Spada, A.. PY - 1973. Y1 - 1973. N2 - Out of 21 patients with active acromegaly, 12 increased plasma GH concentration after TRH injection (200 μg iv). No correlation was found between basal plasma GH levels, plasma GH response to hypoglycemia, arginine, oral glucose load and plasma GH response to TRH. The plasma GH peak often preceded that of TSH. One patient TSH unresponsive to TRH and 2 patients poorly responsive to TRH showed a rise in plasma GH. In 1 patient who increased both TSH and GH after TRH, the plasma response was abolished by triiodothyronine administration, while that of plasma GH remained unchanged. Since it was demonstrated that a releasing hormone acts activating the adenylcyclase system after binding to specific cellular receptors, it is suggested that in some ...
A hyperfunctioning growth hormone - secreting pituitary adenoma is the most common cause of acromegaly. Rarer causes are ectopic or hypothalamic growth hormone releasing hormone-secreting tumor. Since the signs and symptoms of acromegaly are indolent, the time from onset of signs and symptoms to diagnosis of acromegaly is long, usually taking years. The pituitary adenomas that cause growth hormone excess are usually large and are easily identified on routine MRI imaging of the sella. Treatment would then involve resection of the pituitary adenoma via transsphenoidal surgery. In rare cases, a pituitary MRI may show negative results. A contrast enhanced CT scan of the chest and abdomen is the next step to detect ectopic sources of GH or GH releasing hormone (GHRH) production. Acromegaly without imaging evidence of a pituitary macroadenoma or an ectopic source is very rare. Lonser et al., reported 6 patients (mean age 56 years) with signs, symptoms and biochemical evidence of acromegaly without ...
Acromegaly ACROMEGALY Acromegaly is caused by GH secretion usually from a macroadenoma. Etiology- Pituitary adenoma Extrapituitary tumour GHRH- mediated acromegaly is most common cause is abdominal carcinoid tumour. Clinical features- Excessive GH secretion Before closure of epiphyses- tall stature & gigantism After closure of epiphysis- acromegaly Prognathism Nasal sinus enlargement Increased heel pad thickness Widened space between lower incisor teeth & defect in mandible Enlargement of hands & feet Carpel tunnel syndrome Osteoarthritis Hyperhidrosis Muscle hypertrophy Cardiomegaly, macroglossia & thyroid gland enlargement Diabetes mellitus Investigations- Screening- random serum IGF- 1 elevated Oral glucose tolerance test with GH measure confirms acromegaly Prolactin elevated Treatment- Surgical- Trans- sphenoidal surgery- first line of treatment Radiotherapy is the second line of treatment. Drugs- somatostatin ananlogues (lanreotide)- lowers GH levels Dopamine agonist (Cabergoline) Exam Important
Objective: Acromegaly is a rare pituitary disease due to excessive secretion of GH. Insulin resistance, impaired glucose tolerance (IGT) and diabetes mellitus (DM) are common features in acromegaly. Seventy-four active acromegalic patients were retrospectively evaluated in order to determine the impact of family history for diabetes mellitus on glucose tolerance, insulin resistance and beta-cell function.. Patients and methods: We studied 74 patients with active acromegaly (mean IGF-1 value: 576.8±35.6 ng/ml ES; mean GH value on OGTT nadir 11.8±1.8 ng/ml ES), 29 males and 45 females, aged 50.4±14.1 years, body mass index (BMI) 28.1±4.3 (kg/m2). All patients underwent an oral glucose tolerance test (OGTT): GH, blood glucose and insulin were sampled at 0, 30, 60, 90, 120 minutes. Insulin resistance was evaluated with HOMA2-IR, Quicki and ISI0.120; beta cell function was evaluated with HOMA2%-ß index.. Results: Acromegalic patients with a positive family history for diabetes mellitus showed an ...
Pituitary adenomas are benign neoplasms arising from cells of the anterior pituitary gland and constitute 10-15% of intracranial tumors. From the clinicopathological point of view, they are divided into as somatotroph adenomas, which produce growth hormone; lactotroph adenomas, which produce prolactin; thyrotroph adenomas, which produce thyroid-stimulating hormone (TSH); corticotroph adenomas, which produce adrenocorticotropic hormone ACTH); and gonadotroph adenomas, which produce gonadotropin [1]. It is extremely unusual for the dentist to suspect a somatotroph pituitary adenoma during a periodontal maintenance visit.. Patients with acromegaly are usually diagnosed late (,3 years) and at very advanced stages of the disease. In our case, the time to diagnosis was approximately two years; when OSAS was diagnosed, acromegaly should have been suspected. About 40% of cases of acromegaly are diagnosed by internists, and they may also be diagnosed by specialists in sleep obstructive disorders or ...
Growth Hormone-Secreting Pituitary Adenoma: A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.
In this paper, we have described a high prevalence of DM and ECMDs in patients with acromegaly. Over 50% of our patients had DM, either overt and already being treated with diet or medication or diagnosed with an OGTT during our study. In a further 26% of subjects, the OGTT revealed the presence of IFG or IGT, together named ECMDs. The prevalence of both DM and ECMDs was significantly higher in patients with acromegaly than in the general population or in a population with a high risk of diabetes; only 22% of subjects with acromegaly were normoglycaemic. This report on glucose metabolism derangements in a large population of patients with acromegaly in Russia confirms earlier reports demonstrating the prevalence of ECMDs to be higher in these patients than in the general population (2, 5, 6, 7).. In accordance with these earlier observations, we observed those patients who had already developed diabetes or ECMDs to be older and have a higher BMI, and a longer duration of acromegaly. In addition, ...
... is an online community resource committed to raising awareness of the early signs and symptoms of acromegaly and creating a safe space for those affected by this rare condition to share their experiences.. Visit our acromegaly community resources page for our partnering organizations joined together to combat stigmas surrounding acromegaly, promote early diagnosis, and push for optimal treatment and care for all patients with acromegaly worldwide.. ...
Hello acromegaly friends and families, We have lots to share with Ottawa Acromegaly Awareness and Support Network. President Dianne Sauvé and myself (Heather Elder, VP) recently attended the 2019 International Acromegaly Conference, held March 20-22 in New Orleans. This incredible event allowed us to meet over 200 individuals connected to the acromegaly community-patients from around…
Somatotroph pituitary adenoma is the most frequent cause of acromegaly. A transsphenoidal removal of the tumor is used as the first line treatment. Somatostatin analogs are used as to whether recovery was not obtained after surgery or pituitary surgery was contraindicated. Previous studies with somatostatin analogs have shown a drop in plasma GH and IGF-1 levels and a reduction in adenoma size in 75 and 25% of patients respectively. Retrospective studies suggest that a treatment with somatostatin analogs performed before surgery may be of interest to improve anesthesic conditions and surgical outcome. The aim of present study is to prospectively evaluate the interest of a first line treatment with a long-acting somatostatin analog (Sandostatin) before performing a pituitary surgery in acromegalic patients with either a micro or a macroadenoma to improve peri-operative conditions and hopefully surgical outcome. After informed consent, untreated acromegalic patients will be included and randomly ...
Lonser R, Kindzelski BA, Mehta GU, Jane JA Jr., Oldfield EH. Acromegaly without imaging evidence of pituitary adenoma. J Clin Endocrinol Metab. 2010;95(9):4192-6. PMCID: PMC2936064. https://doi.org/10.1210/jc.2010-0570.. Khandelwal D, Khadgawat R, Mukund A, Suri A. Acromegaly with no pituitary adenoma and no evidence of ectopic source. Indian J Endocrinol Metab. 2011;15(Suppl 3):S250-2. PMCID: PMC3183531. https://doi.org/10.4103/2230-8210.84878.. Katznelson L, Laws E, Melmed S, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51. PMID: 25356808. https://doi.org/10.1210/jc.2014-2700.. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicenter study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859-68. PMID: 17465997. PMCID: PMC1974838. ...
To study the effect of chronic excess growth hormone on adipose tissue, we performed RNA sequencing in adipose tissue biopsies from patients with acromegaly (n = 7) or non-functioning pituitary adenomas (n = 11). The patients underwent clinical and metabolic profiling including assessment of HOMA-IR. Explants of adipose tissue were assayed ex vivo for lipolysis and ceramide levels. Patients with acromegaly had higher glucose, higher insulin levels and higher HOMA-IR score. We observed several previously reported transcriptional changes (IGF1, IGFBP3, CISH, SOCS2) that are known to be induced by GH/IGF-1 in liver but are also induced in adipose tissue. We also identified several novel transcriptional changes, some of which may be important for GH/IGF responses (PTPN3 and PTPN4) and the effects of acromegaly on growth and proliferation. Several differentially expressed transcripts may be important in GH/IGF-1-induced metabolic changes. Specifically, induction of LPL, ABHD5, and NRIP1 can ...
The literature on an association between acromegaly and cancer is particularly abundant on either colorectal cancer or thyroid cancer, and an endless debate is ongoing whether patients with acromegaly should be submitted to specific oncology screening and surveillance protocols. The aim of the present work is to review the more most recent data on the risk of either colorectal cancer or thyroid cancer in acromegaly and discuss the opportunity for specific screening in relation to the ...
Acromegaly is a rare disease commonly caused by a GH secreting pituitary adenoma, frequently a macroadenoma (>1cm) [3]. The management ofacromegaly should be always dedicated to improve the quality of life, signs and symptoms of the disease. The cure in acromegaly is mainly biochemical, indicated by normalization of GH below 2.5ug/L, GH suppression to 1ug/L during an Oral Glucose Tolerance Test (OGTT) and IGF-1 level normalization for age and gender [1]. In some cases, despite of establishing the cure of the disease, recurrence or persistence is possible.. Transspenoidal microsurgery has been demonstrated to be an effective way to treat acromegalic patients, however rates of cure with surgery alone have been reported only to 60% [4]. Thus at least 40% of patient will be diagnosed with either persistent disease or recurrence [1,4], and will require further medical or surgical intervention.. This particular patient presented as recurrent acromegaly after 18 years initial surgical treatment, with ...
en] Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been shown to develop acromegaly. In 4 patients, clinical follow-up, and biological screening allowed to confidently exclude MEN1. Absence of mutation in the MEN1 gene after direct DNA analysis in 2 pedigrees reinforces the conviction that the families do not have MEN1. In families 1 and 2, diagnosis was made at a very early age and voluminous adenomas with suprasellar expansion were already present at the time of diagnosis. We review the 20 previous reports of familial acromegaly, some of them questionable. Our 3 families, combined with some other published pedigrees, allow the delineation of a familial form of acromegaly, distinct from MEN1. Dominant inheritance with reduced, age-dependant penetrance is the most parsimonious model to explain the recurrences. Gs protein pathway could be the site of ...
PURPOSE:. Early diagnosis is a success factor for the prevention of long-term comorbidity and premature death in patients with acromegaly, but large-scale data on the diagnostic process and disease management are scarce. Therefore, we aimed to evaluate the diagnostic process, implementation of treatment and changes in life situation in patients with acromegaly, focusing on sex-specific differences.. METHODS:. Non-interventional patient-reported outcome study. 165 patients with clinically and biochemically proven acromegaly were questioned about the diagnostic process and utilization of health care by means of a self-developed standardized postal survey including questions on acromegaly symptoms experienced before diagnosis, number and specialty of consulted doctors, time to diagnosis and aftercare.. RESULTS:. The diagnostic process took 2.9 (SD 4.53) years, during which 3.4 (SD 2.99) physicians were consulted. Women waited longer [4.1 (SD 5.53) years] than men [1.6 (SD 2.69) years; p = 0.001] ...
Acromegaly: Definition and history, causes, signs and symptoms of acromegaly. Treatment, radiotherapy, and homeopathic medicines for acromegaly treatment.
Acromegaly is known to be associated with insulin resistance. Visceral adipose tissue is increased in patients with insulin resistance and we aimed to investigate a visceral adipose tissue content as a possible marker of insulin resistance in diabetic and nondiabetic acromegalic patients. We compared 16 diabetic and 16 nondiabetic acromegalic patients for fasting blood glucose (FBG), insulin and visceral adipose tissue content calculated from abdominal computer tomography. All patients were active acromegalic. Diabetic patients were well controlled with diet alone or diet and oral antidiabetic drugs. Diabetic patients were significantly older than nondiabetics(51.94±10.17 vs 41.38±13.43 years, P=0.018). GH and IGF-1 levels were similar in both groups. Visceral adipose tissue content did not differ between diabetic and nondiabetic patients. Age, GH, IGF-1, FBG and fasting insulin were not correlated with adipose tissue content. In conclusion, concomittant well controlled diabetes might not ...
A 56-years-old woman was referred to our unit for partially treated acromegaly. She had a high level of insulin growth factor. She did not complain of any pulmonary symptoms and was a non-smoker. Physical examination revealed clinical features of acromegaly. She had a 13 mm pituitary adenoma and was proposed for surgical intervention. Her chest X-ray showed a right paracardiac tumor. Computed tomography scan revealed a large right-sided fowler tumor. Pituitary surgery was cancelled and lobectomy after biopsy with lymph nodes excision was performed through thoracotomy. Histological study of the tumor revealed a medium differentiated epidermoid carcinoma with positive lymph nodes and extension to pleura. She was referred to chemotherapy protocol. Association between carcinoma and acromegaly has previously been reported. Most common tumors are colorectal and thyroid neoplasia. As we see in this case report, we need to consider other carcinomas in acromegalic patients like pulmonary carcinoma, despite their
Basel, September 26, 2014 - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Signifor® (pasireotide) long acting release (LAR) formulation to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA)[2]. If approved in the EU, this next-generation SSA could fill a current unmet need, providing a new therapeutic option for the approximately 45% of acromegaly patients whose growth hormone (GH) or insulin-like growth factor-1 (IGF-1) levels remain inadequately controlled despite treatment with currently available SSAs[2],[3].. Affecting an estimated one to two patients per 10,000 people in the EU, acromegaly is a rare, debilitating endocrine disorder caused by the excess production of GH and IGF-1[1],[4]. The disease is caused by a non-cancerous tumor in the pituitary gland[1]. ...
TY - JOUR. T1 - Arthropathy in acromegaly. T2 - a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. AU - Study Group on Motor Disability in Acromegaly of the Italian Society of Endocrinology. AU - Fatti, L M. AU - Cangiano, B. AU - Vitale, G. AU - Persani, L. AU - Mantovani, G. AU - Sala, E. AU - Arosio, M. AU - Maffei, P. AU - Dassie, F. AU - Mormando, M. AU - Giampietro, A. AU - Tanda, L. AU - Masiello, E R. AU - Nazzari, E. AU - Ferone, D. AU - Corbetta, S. AU - Passeri, E. AU - Guaraldi, F. AU - Grottoli, S. AU - Cannavò, S. AU - Torre, M L T. AU - Soranna, D. AU - Zambon, A. AU - Cavagnini, F. AU - Scacchi, M. PY - 2019/10. Y1 - 2019/10. N2 - PURPOSE: Arthropathy is a common and disabling complication of acromegaly. Since in this condition radiological findings rarely correspond to functional impairment, we elected to quantify in a large cohort of acromegalic patients: the degree of motor disability compared with data from ...
In patients who do not achieve biochemical remission by surgery, options for adjunctive therapy include medical therapy and radiation therapy. There are three types of medical therapy that can be offered. 1. Somatostatin Analogs The most commonly used class of medications used to treat acromegaly are somatostatin analogs. These long-acting analogs of the endogenous inhibitor of GH, somatostatin, will suppress GH and thereby lower circulating IGF-I levels. In most patients, they retard tumor growth, and some patients have significant tumor shrinkage. Complete biochemical remission occurs in 20% to 60% of patients. Somatostatin analogs work by activating somatostatin receptors on the tumor cells, but variability in the expression and density of the specific receptor subtypes activated by these analogs results in variable patient responses. Three analogs are clinically available: octreotide LAR (long-acting release), lanreotide autogel, and pasireotide LAR. These are given as intramuscular ...
OBJECTIVE: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. METHODS: Cross-sectional and retrospective study of thirty cases treated over a period of two decades. RESULTS: 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients underwent transphenoidal surgery, whichwas associated with somatostatin receptor ligands in 11 patients (39.3%), somatostatin receptor ligands + radiotherapyin 5 patients (17.8%), radiotherapy in 3 patients (10.7%), and radiotherapy + somatostatin receptorligands + cabergoline in 1 patient (3.6%). Additionally, 2 patients underwent radiotherapy and surgeryalone. Six patients received somatostatin receptor ligands before surgery, and 2 were not treated due to refusal and death. Nine patients have died, and 20 are being followed; 13 (65%) have growth hormonelevels o1 ng/mL, and 11 have normal insulin-like growth factor 1 levels. CONCLUSION: The current treatment
VetVine is an accredited Continuing Education provider for veterinary professionals and resource of expert-driven pet health information for pet owners. This is the forum topic view page. Feline acromegaly (hypersomatropism or HST) is a spontaneously occurring condition caused by a growth hormone (GH) secreting pituitary tumor (somatotrophinoma). Studies estimate 1 in 3 to 1 in 5 diabetic cats have acromegaly (HST)-induced diabetes mellitius.  Cats with high levels of growth hormone exhibit insulin resistance, arthropathy, general abdominal organ enlargement, and cardiovascular disease. Diabetic cats affected by acromegaly are frequently difficult to control with insulin alone, and controlling glucose levels will not manage other aspects of the disease.  In humans with HST, treatment options include surgical removal of the pituitary tumor, radiation treatment and medical treatment. One form of medical treatment is the use of somatostatin analogs, the drug form of choice in most patients. To
FDA Approval for Enzymatic Hemoglobin A1c Assay Kit. When insulin is not NPH and PZI and various Please note that some insulin formulations require refrigeration and others Diabeteksen hoidon osaamiskeskuksia on aikuisin diabeteksen hoito toteutuisi psntisesti perusterveydenhuollon hyvinvointikeskuksissa joiksi Oulu (which can contribute to high blood pressure). Diabetes And Chicken Nuggets Mellitus Prevalence Acromegaly Patients can Coffee Bean Extract Help "The green coffee [extract] "To say that something can prevent or delay diabetes is almost impossible to prove unless Paul Carlyle Diabetes Miracle Cure Program Review under a cold shower will stimulate your Cure Program Review: Miracle Diabetes Cure Guide Suspected Drug Lab Discovered after Flash Fire Injures Man Near Downtown Detailing the Dangers of Chicken Jerky.. If your fasting is consistently above 95 or your post eating Continuing Education for Pharmacists Diabetes Education: This list of continuing education activities is provided ...
Radiating the Tumor details my experiences living with acromegaly. The journey begins where the tumor regains its strength, working to take over a second time.. Within the posts I share my attempts to find peace of mind, to heal and my hopes for remission. I detail my thoughts and feelings throughout stereotactic radiation treatments. And continue as, well, one does in life.. Originally diagnosed with acromegaly due to a hormone producing pituitary macro-adenoma in early 2014, in May of 2014 I underwent transsphenoidal surgery at Johns Hopkins Hospital in Baltimore, Maryland.. I was at the beginning, and I remain today, committed to fighting for peace of mind free from the pains of acromegaly. I am determined that this rare disease will not claim me as its victim.. For more information, kindly complete the contact form below. Wishing you and yours the very best.. Copyright © 2017 . All rights reserved.. ...
ICD-10 Code: E22.0. Definition: Acromegaly is caused by overproduction of growth hormone, most commonly by a benign pituitary tumor (pituitary adenoma). Acromegaly may be accompanied by distinct findings in the musculoskeletal system that may contribute to early detection and diagnosis.. Cardinal Findings: Excess growth hormone causes acromegaly in adults and, if the onset is before epiphyseal closure, gigantism in children. Clinically, patients develop distinctive coarse facial features; thickening of the skin; enlarged mandible, hands, and feet; prominent forehead and supraorbital ridging; enlarged tongue and enlarged viscera; hirsutism; oily skin; and excessive sweating. The musculoskeletal complaints result from premature osteoarthritis, kyphosis of the spine, pseudogout, entrapment neuropathies [e.g., carpal tunnel syndrome (CTS)]. Many patients complain of nonspecific arthralgias affecting the shoulder, knees, hips, and spine.. Complications: Increased cardiovascular morbidity and ...
Address all correspondence and requests for reprints to: J. O. L. Jørgensen, Medical Department M, Aarhus University Hospital, Norrebrogade 44, DK-8000 C Aarhus, Denmark. E-mail: [email protected] .. Context: Pegvisomant is a GH receptor antagonist that blocksthe peripheral actions of GH in acromegaly. Pegvisomant, incontrast to somatostatin (SMS) analogs, does not suppress theactivity of the GH-producing adenoma.. Objective: We assessed the effects of cotreatment with pegvisomantand SMS in acromegaly on GH secretion, IGF-I levels, and glucosetolerance.. Design, Patients, and Interventions: Eleven patients with persistentdisease despite previous therapy underwent the following fixedtreatment algorithm: 1) on SMS therapy, 2) off therapy for 2months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wktreatment with 15 mg/d pegvisomant, and 5) 3-month treatmentwith 15 mg pegvisomant plus SMS. Blood was sampled in the fastingstate and during an oral glucose tolerance test.. Results: Total serum IGF-I ...
Acromegaly may be treated with hormone-suppressing drugs or with radiation to shrink a pituitary tumor, but it is most often treated surgically, by neurosurgeons and otolaryngological (ENT) surgeons. Removing the pituitary tumor is usually a cure for acromegaly. (More about Pituitary and Skull Base Surgery at Weill Cornell.) The neurosurgeons at Weill Cornell who treat acromegaly and the pituitary tumors that cause it are:
Despite availability of multiple treatment modalities, acromegaly sometimes is a challenging condition to treat, and we report a patient whose disease was only controlled with pasireotide. The patient had a sparsely granulated tumour with suprasellar extension and invasion of the cavernous sinus, and these tumours are known to be more difficult to control. Sparsely granulated somatotroph adenomas are commoner among young females, are generally larger than densely granulated somatotroph adenomas, less responsive to somatostatin receptor ligands (1, 2) and more frequently reported to have suprasellar extension and cavernous sinus infiltration (3).. A number of factors in our patient are associated with increased resistance to treatment of acromegaly. Preoperative GH levels are an important predictor of remission in acromegaly (4). Extremely high disease burden is indicated by clinical findings, biochemistry and imaging and could have contributed largely to the poor response to initial treatment in ...
... is a hormonal disorder that results from the pituitary gland producing too much growth hormone (GH). It is most often diagnosed in middle-aged adults, although symptoms can appear at any age. Signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. The condition is usually caused by benign tumors on the pituitary called adenomas. Rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain. Acromegaly is usually treatable but when left untreated, it can result in serious illness and premature death. When GH-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly ...
Clinical trial for Acromegaly , Safety Tolerability and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
Surgery to remove the pituitary tumor that is causing this condition often corrects the abnormal GH. Sometimes, the tumor is too large to be removed completely and acromegaly is not cured. In this case, medicines and radiation (radiotherapy) may be used to treat acromegaly. Some people with tumors that are too complicated to remove by surgery are treated with medicines instead of surgery. After treatment, you will need to see your provider regularly to make sure that the pituitary gland is working normally and that acromegaly does not come back. Yearly evaluations are recommended. ...
Acromegaly is caused when the pituitary gland in the brain produces too much growth hormone (GH). This causes the hands, feet and sometimes other parts of the body grow larger than what they should. It often causes them to look out of proportion compared to the rest of the body. Acromegaly is a serious condition that needs to be diagnosed by a doctor and treated to prevent further health problems. It can be seen by itself or as symptom/part of other conditions as well. ...
CONTEXT: The sexual dimorphism of the somatotroph axis has been documented, but whether the acromegaly-related metabolic alterations are gender-dependent has never been investigated. OBJECTIVE: The aim of the study was to evaluate the impact of gender on the metabolic parameters in acromegaly. DESIGN: We conducted a retrospective, comparative, multicenter study. PATIENTS: The 307 newly diagnosed acromegalic patients included in the study were grouped by gender: 157 men (aged 48.01 ± 14.28 yr), and 150 women (aged 48.67 ± 14.95 yr; of which 77 were premenopausal and 73 postmenopausal). OUTCOME MEASUREMENTS: We measured each component of the metabolic syndrome (MS), hemoglobin A1c, the areas under the curve (AUCs) of glucose and insulin during 2-h oral glucose tolerance test, basal insulin resistance using the homeostasis model assessment of the insulin resistance index, stimulated insulin sensitivity using the insulin sensitivity index, early insulin-secretion rate using the insulinogenic ...
In over 90 percent of acromegaly patients, the overproduction of GH is caused by a benign tumor of the pituitary gland, called an adenoma. These tumors produce excess GH and, as they expand, compress surrounding brain tissues, such as the optic nerves. This expansion causes the headaches and visual disturbances that are often symptoms of acromegaly. In addition, compression of the surrounding normal pituitary tissue can alter production of other hormones, leading to changes in menstruation and breast discharge in women and impotence in men. There is a marked variation in rates of GH production and the aggressiveness of the tumor. Some adenomas grow slowly and symptoms of GH excess are often not noticed for many years. Other adenomas grow rapidly and invade surrounding brain areas or the sinuses, which are located near the pituitary. In general, younger patients tend to have more aggressive tumors. Most pituitary tumors arise spontaneously and are not genetically inherited. Many pituitary tumors ...
Rationale: Acromegaly is the clinical syndrome that results from an excess of growth hormone (GH). Craniofacial and hand disproportions due to soft tissue swelling and new bone formation are highly prevalent in patients with active acromegaly. Besides the cosmetic aspects, these changes can impair the quality of life because of the significant morbidity with respect to oral, maxillofacial and hand pathologies as well as respiratory problems such as sleep apnea and changes in speech. At present it is unclear if these craniofacial and hand disproportions, sleep apnea and speech changes are (partially) reversible after successful treatment. Therefore there is no consensus about the information patients should be given about (partial) recovery of facial and hand disproportions after treatment and how the follow-up with respect to oral, maxillofacial, respiratory and hand pathology should be organized. Facial and hand analysis using a 3D stereophotograph and a 3D fusion model of a 3D stereophotograph ...
Correlation between tumor volume and hormone levels in individual patients would permit calculation of the fraction of tumor removed by surgery, by measuring postoperative hormone levels. The goals of this study were to examine the relationship between tumor volume, growth hormone (GH), and insulin-like growth factor-1 (IGF-1) levels, and to assess the correlation between percent tumor removal and the reduction in plasma GH and IGF-1 in patients with acromegaly. The 3D region of interest-based volumetric method was used to measure tumor volume via MRI before and after surgery in 11 patients with GH-secreting adenomas. The volume of residual tumor as a fraction of preoperative tumor volume was correlated with GH levels before and after surgery. Examination of this potential correlation required selection of patients with acromegaly who 1) had incomplete tumor removal, 2) had precise measurements of initial and residual tumor, and 3) were not on medical therapy. Densely granulated tumors produced ...
In the last 2 years we have had a Nutritionist, Endocrinologist, Psychologist and the Division Head of Clinical Chemistry at St. Pauls Hospital in Vancouver as guest speakers. To date we have 32 members that are actively involved with the support group. This support group is for all Acromegaly patients and we do not restrict patient intake to BC as patients from Alberta and Saskatchewan are more than welcome which is why we have named this site Western Acromegaly ...
Current data suggests that most cases of isolated acromegaly are not due to an underlying hereditary (genetic) cause that gets passed through a family. However, when acromegaly begins in childhood or adolescence the gene aryl hydrocarbon receptor interacting protein, [i]AIP[/i], is thought to be a s
New life-saving treatments for Acromegaly in clinical trial on Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
If the IGF-I level proves to be normal in a patient who has definite clinical features of acromegaly then there are several possibilities. Firstly, some patients with acromegaly have tumors that hemorrhage and auto infarct then undergo necrosis. There growth hormone and IGF-I levels will fall to normal and sometimes a develop growth hormone deficiency. Some have varying degrees of hypopituitarism. Many of these patients have a partial or nearly empty sella, expansion of the sella turcica, and an irregular pituitary gland. Thus, MRI can be useful to provide insight into the fact that an acromegaloid patient with normal biochemistry may have once had a pituitary tumor. Next, there is a disorder called acromegaloidism where patients may have thickened furrows on the skin of the scalp (cutis gyrata vertica), enlarged brows, and prognathism. Of course, some patients have familial prognathism that is unrelated to growth hormone secretion. Lastly, the syndrome of insulin resistance can produce an ...
First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pre-treatment biomarkers might affect biochemical response to fg-SRLs.To identify clinical predictors of the biochemical response to fg-SRLs monotherapy defined as biochemical- (IGF-1 ≤1.3 x upper limit of normal; ULN), partial- (,20% relative IGF-1 reduction without normalization) and non-response (≤20% relative IGF-1 reduction), and IGF-1 reduction.Retrospective multicenter study.Eight participating European centers.We performed a meta-analysis of participant data from two cohorts (Rotterdam and Liège acromegaly survey (LAS), 622 out of 3520 patients). Multivariable regression models were used to identify predictors of biochemical response to fg-SRL monotherapy.Lower IGF-1 concentration at baseline (OR=0.82, [0.72-0.95] IGF-1 ULN, p=0.0073) and lower bodyweight (OR=0.99, [0.98-0.99] kg, ...
Well today is the first anniversary of my surgery for Acromegaly that I had at Hope Hospital (Salford Royal Hospital) in Manchester (UK). Its hard to believe its been a year. It seems so recent in a way to some extents, but Ive really been enjoying things. Im basically a lot more chilled out that…
Acromegaly is an alternative diagnosis. From photographs of Rachmaninov in the 1920s and his portrait by Konstantin Somov in ... Speculations about Marfan syndrome and acromegaly[edit]. Along with his musical gifts, Rachmaninoff possessed physical gifts ... Melanoma is associated with acromegaly and may have been a final clue to Rachmaninov's diagnosis. ... although carpal tunnel syndrome or simply swelling and puffiness of the hands associated with acromegaly may have been the ...
Acromegaly. 1,512. 2012[83]. 5%. Signifor (pasireotide) Cushing's disease[87][88] Simulect (basiliximab). Prevention of ...
For example, acromegaly results from excessive secretion of growth hormone (GH) often being released by a pituitary adenoma. ... Scacchi, Massimo; Francesco Cavagnini (2006). "Acromegaly". Pituitary. 9 (4): 297-303. doi:10.1007/s11102-006-0409-4. ISSN 1573 ...
In acromegaly, a condition caused and maintained by highly elevated GH/IGF-1 levels, overall, there appears to be little or no ... Jenkins PJ (2004). "Acromegaly and cancer". Horm. Res. 62 Suppl 1: 108-15. doi:10.1159/000080768. PMID 15761242. Nathan A. ... In addition, there appears to be an increased risk of colorectal cancer and pre-malignant tubular adenomas in acromegaly. In ... Loeper S, Ezzat S (2008). "Acromegaly: re-thinking the cancer risk". Rev. Endocr. Metab. Disord. 9 (1): 41-58. doi:10.1007/ ...
Insulin is the principal hormone that regulates the uptake of glucose from the blood into most cells of the body, especially liver, adipose tissue and muscle, except smooth muscle, in which insulin acts via the IGF-1. Therefore, deficiency of insulin or the insensitivity of its receptors play a central role in all forms of diabetes mellitus.[55] The body obtains glucose from three main sources: the intestinal absorption of food; the breakdown of glycogen, the storage form of glucose found in the liver; and gluconeogenesis, the generation of glucose from non-carbohydrate substrates in the body.[56] Insulin plays a critical role in balancing glucose levels in the body. Insulin can inhibit the breakdown of glycogen or the process of gluconeogenesis, it can stimulate the transport of glucose into fat and muscle cells, and it can stimulate the storage of glucose in the form of glycogen.[56] Insulin is released into the blood by beta cells (β-cells), found in the islets of Langerhans in the pancreas, ...
Commonly, patients will also have acromegaly with enlargement of the hands, feet, and jaw. After puberty, additional symptoms ... acromegaly; insulin resistance; and high serum levels of triglycerides. Genetic testing can also confirm the disease, as ...
Conversely, acromegaly and gigantism are conditions of GH and IGF-1 excess usually due to a pituitary tumor, and are ... Adigun O, Mesfin F (2017). "Acromegaly". PMID 28613738. De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM ...
"Gigantism and Acromegaly: Practice Essentials, Background, Pathophysiology and Etiology". 2017-01-07. "Gigantism and Acromegaly ... See acromegaly for additional treatment possibilities. Gigantism, also known as giantism (from Greek γίγας gigas, "giant", ... Characteristics more similar to those seen in acromegaly may occur in patients that are closer in age to adolescence since they ... Acromegaly Deep-sea gigantism Dwarfism Giant of Castelnau Growth hormone Homo heidelbergensis Hypothalamic-pituitary-somatic ...
Gigantism and Acromegaly at eMedicine Aguirre, Alfredo (2014). Cellular Endocrinology in Health and Disease. Elsevier. p. 24. ... ISBN 978-0-12-408134-5. "Acromegaly". NIH. National Institute of Diabetes and Digestive, Kidney Disease. 2014. Retrieved 28 ... Hyperpituitarism~treatment at eMedicine "National Guideline Clearinghouse , Acromegaly: an Endocrine Society clinical practice ... gigantism or acromegaly, which can be identified by clinical and radiographic results. Cushing's disease diagnosis is done with ...
Factors which contribute to insulin resistance include obesity and endocrine diseases such as acromegaly. Acromegaly affects 20 ...
acrobatique) acromegaly (Fr. acromégalie) across (Anglo Fr. an cros) act (Old Fr. acte) action activity, (Middle French ...
Duarte FH, Jallad RS, Bronstein MD (November 2016). "Estrogens and selective estrogen receptor modulators in acromegaly". ...
Somavert (pegvisomant) for Acromegaly. Sutent (sunitinib) for cancer and a chemotherapy drug. Toviaz (fesoterodine) for ...
The 1858 image of Pio Pico was used as an example of florid acromegaly in the scientific review paper "Acromegaly Pathogenesis ... Acromegaly is usually a fatal illness if untreated; 80% of patients die within 10 years of the diagnosis. But, Pico survived 36 ... With a height of 67 inches in his forties, his acromegaly must have begun after puberty, or he would have manifested gigantism ... The 1852 daguerreotype of Pio Pico may be the earliest objective image of acromegaly ever recorded since the disease was not ...
After completing clinical trials, it was approved for the treatment of acromegaly by the FDA in 2003 and marketed by Pfizer. ... It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and ... Pegvisomant (trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. ... "Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from ...
Salenave, Sylvie; Boyce, Alison M.; Collins, Michael T.; Chanson, Philippe (2014-6). "Acromegaly and McCune-Albright Syndrome ...
"Carpel Tunnel Syndrome in Acromegaly". Treatmentandsymptoms.com. Archived from the original on 2016-01-26. Retrieved 2011-10-05 ... acromegaly, and use of corticosteroids and estrogens. Carpal tunnel syndrome is also associated with repetitive activities of ... the hand and wrist, in particular with a combination of forceful and repetitive activities Acromegaly causes excessive ...
In 2013, Pesi was diagnosed with Acromegaly while filming 42. Alfredo Quiñones-Hinojosa removed his tumor, and Pesi credits "Dr ... "Gino Anthony Pesi: Actor and Acromegaly Survivor". "Instagram post by Gino Anthony Pesi • Mar 3, 2017 at 11:18pm UTC". ...
Estrogens have been used to treat acromegaly. This is because they suppress insulin-like growth factor 1 production in the ...
It is sometimes a result of acromegaly. This condition is colloquially known as lantern jaw, as well as Habsburg jaw, Habsburg ...
Acromegaly patients often also have diabetes mellitus. There is a transient form of acromegaly which can affect females at the ... Acromegaly is also possible from a somatotroph adenoma. The hormone somatostatin can also be useful in treatment. Since ... Acromegaly (also known as hypersomatotropism) is a hormonal condition resulting from over-secretion of the growth hormone ... Because the bone plates close when entering maturity, the continued growth of acromegaly is not of normal proportions. Most ...
De Herder, W. W. (2009). Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early ... but doubted that he had acromegaly as his body was proportional and there was no sign of hypogonadism. However, he had an ...
Duarte FH, Jallad RS, Bronstein MD (2016). "Estrogens and selective estrogen receptor modulators in acromegaly". Endocrine. 54 ... and osteoporosis in women Prevention of tall stature in tall adolescent girls Suppression of IGF-1 levels in acromegaly and ...
The nose may be stimulated to grow in acromegaly. Some people choose to get rhinoplasty to change the aesthetic appearance of ...
He is believed to have been afflicted with acromegaly. Rainer was born in Graz, Austria-Hungary. In 1918, at age 18, he was ...
... Posted by kim drew ® on 5:10 AM ...
Acromegaly and pituitary gigantism is E22.0. E22.0 is a VALID/BILLABLE ICD10 code, i.e it is valid for submission for HIPAA- ... Acromegaly and pituitary gigantism E22.0. * E22.0. is a billable/specific ICD-10-CM code that can be used to indicate a ...
... acromegaly, vitamin A deficiency, etc. We report two rare cases of hypercementosis associated with systemic lupus erythematosus ... acromegaly, vitamin A deficiency, etc. We report two rare cases of hypercementosis associated with systemic lupus erythematosus ... acromegaly, vitamin A deficiency, etc. We report two rare cases of hypercementosis associated with systemic lupus erythematosus ... acromegaly, vitamin A deficiency, etc. We report two rare cases of hypercementosis associated with systemic lupus erythematosus ...
Brush of the patient with acromegaly( a) and healthy brush( b) Symptomatic Progression of gigantism is actually difficult to ...
This complex genetic disorder may have other endocrine syndromes like hyperthyroidism, acromegaly, and Cushing syndrome. ...
Localized forms can be seen in benign cementoblastoma, florid cemento-osseous dys- plasia, acromegaly, calcinosis and some ... Localized forms can be seen in benign cementoblastoma, florid cemento-osseous dys- plasia, acromegaly, calcinosis and some ...
Acromegaly. *Prolactinoma. *Prolactinoma - males. *Multiple endocrine neoplasia (MEN) type 2. *Multiple endocrine neoplasia ( ...
What are the Symptoms of Acromegaly?. *What are the symptoms of Adrenal Insufficiency? ...
Definition Acromegaly is a disease in which an abnormality in the pituitary gland [1] leads to an oversecretion of growth ... Acromegaly and gigantism. Definition. Acromegaly is a disease in which an abnormality in the pituitary gland leads to an ... Web site: ,www.acromegaly.org,.. WEB SITES. Shim, Melanie, and Pinchas Cohen. "Gigantism and Acromegaly." eMedicine, July 29, ... Acromegaly and Gigantism. Definition. Acromegaly is a disorder in which the abnormal release of a particular chemical from the ...
Acromegaly (th); Acromegaly (ml); Acromegali, Acromegaly (tr); Ακρομεγαλία (el); Hyperpituitarismus, Pachyakrie (de); ... i-acromegaly (zu); 肢端肥大症 (zh-sg); Акромегалия (kk-cyrl); akromegali (nn); akromegali (nb); Akromeqaliya (az); acromegaly (en); ... Media in category "Acromegaly". The following 35 files are in this category, out of 35 total. ... Hands and feet of a patient suffering from acromegaly Wellcome L0061368.jpg 3,967 × 5,695; 2.29 MB. ...
there are three ways to treat acromegaly: *surgery ... How is acromegaly treated?. ANSWER Your doctor will work with ...
Acromegaly is a condition in which there is too much growth hormone (GH) in the body. ... Acromegaly is a rare condition. It is caused when the pituitary gland makes too much growth hormone. The pituitary gland is a ... Melmed S. Acromegaly. In: Jameson JL, De Groot LJ, de Kretser DM, et al, eds. Endocrinology: Adult and Pediatric. 7th ed. ... Sometimes, the tumor is too large to be removed completely and acromegaly is not cured. In this case, medicines and radiation ( ...
Acromegaly can cause several complications if left untreated. These complications, like the symptoms of the disease, are ... Severe headache may be seen as a complication of acromegaly.. *As a complication of surgery or radiation therapy, acromegaly ... Those with acromegaly are at risk of arthritis and joint pains as well. This is called Acromegalic arthropathy and affects up ... Heart disease - acromegaly increases the risk of ischemic heart disease leading to a worsening of risk of heart attacks and ...
Acromegaly is an endocrine disorder where there is a hormonal imbalance in the body. The condition is caused by too much growth ... Symptoms of acromegaly. Without treatment acromegaly can cause severe complications and even death. Acromegaly is treatable in ... Gigantism and acromegaly. If the disorder occurs in childhood, it leads to gigantism rather than acromegaly. In children excess ... Those with acromegaly usually have no growth of their limbs. However bones of the hands, feet, and face can still grow and ...
... due to development of complications in the majority of patients with acromegaly. Traditionally, acromegaly is considered as a ... Acromegaly is caused by hypersecretion of growth hormone (GH) and consequently of insulin-like growth factor-I (IGF-1) due to ... Osteoarticular Changes in Acromegaly. Zdenko Killinger, Martin Kužma, Lenka Sterančáková, and Juraj Payer ...
What changes are seen among patients with acromegaly after long-term multimodality therapy? Are these patients able to be ... FDA Approves First Oral Somatostatin Analog for Acromegaly * A Consensus on the Diagnosis and Treatment of Acromegaly ... Acromegaly is caused by excess secretion of growth hormone (GH), typically arising from tumors located in the pituitary gland.[ ... Biochemical Control in Acromegaly With Multimodality Therapies. Outcomes From a Pituitary Center and Changes Over Time. ...
Care guide for Acromegaly. Includes: possible causes, signs and symptoms, standard treatment options and means of care and ... What is acromegaly?. Acromegaly is a condition caused by increased levels of growth hormone (GH). GH helps your body use energy ... What problems are caused by acromegaly?. Acromegaly can increase your risk for any of the following:. *Heart disease or high ... How is acromegaly diagnosed?. *Blood tests are done to measure your GH and other hormone levels. You may be told not to eat or ...
Acromegaly and gigantism are due to excess GH production, usually as a result of a pituitary adenoma. The incidence of ... Acromegaly is a disabling disease that is associated with increased morbidity and reduced life expectancy. The diagnosis is ... Clinical Manifestations and Diagnosis of Acromegaly. Gloria Lugo,1 Lara Pena,2 and Fernando Cordido1,3 ... Manifestations of acromegaly are varied and include acral and soft tissue overgrowth, joint pain, diabetes mellitus, ...
Learn about our approach to treating Acromegaly and find information on signs and symptoms, diagnosis, and resources and ... Acromegaly. Resources & Support At UCSF Health, we are renowned for our highly specialized and cutting-edge medical care. Along ...
Acromegaly: Are You Missing the Signs? Acromegaly: Are You Missing the Signs?. For patients with acromegaly, 10 years or more ... Understanding the Nuanced Management of Acromegaly Understanding the Nuanced Management of Acromegaly. Acromegaly is a rare ... Predictors of Quality of Life in Patients With Acromegaly Predictors of Quality of Life in Patients With Acromegaly. Certain ... Patients and Doctors on Different Pages for Acromegaly Symptoms Patients and Doctors on Different Pages for Acromegaly Symptoms ...
... and treatment of acromegaly, a rare disease that causes your hands, feet, face, and other parts of your body to swell and grow ... Acromegaly Facts and Treatments. Your Guide To. Acromegaly Facts and Treatments. Acromegaly Facts and Treatments Acromegaly ... To learn more about acromegaly, visit the acromegaly website of the Pituitary Network Association. You can get information ... National Endocrine and Metabolic Diseases Information Service: "Acromegaly.". UpToDate: "Patient information: Acromegaly ( ...
Acromegaly - Pipeline Review, H2 2016, provides an overview of the Acromegaly pipeline... ... Global Markets Directs, Acromegaly - Pipeline Review, H2 2016, provides an overview of the Acromegaly pipeline landscape. ... Acromegaly - Pipeline Review, H2 2016. Press Release • Oct 25, 2016 09:06 EDT ... The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and ...
AcromegalyGrowth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and ... in treatment of subjects with acromegaly and its effects on acromegaly related co-morbidities. ... in treatment of subjects with acromegaly and its effects on acromegaly related co-morbidities. ... Subjects with diagnosed acromegaly who were already being treated with Somavert® or were to start treatment with Somavert® were ...
ACROMEGALY - A RARE DISEASE by meet akbari , This newsletter was created with Smore, an online tool for creating beautiful ... person suffering from acromegaly Acromegalic legs X-ray of a person having acromegaly ... Early treatment of acromegaly can prevent these complications from developing or becoming worse. If untreated, acromegaly and ... Acromegaly occurs in about 6 of every 100,000 adults. It is caused by abnormal production of growth hormone after the skeleton ...
  • Although most of the cases are idiopathic, several local and systemic factors are also linked to this condition, such as Paget's disease, acromegaly, vitamin A deficiency, etc. (elsevier.com)
  • In this case, medicines and radiation (radiotherapy) may be used to treat acromegaly. (medlineplus.gov)
  • A short-acting formulation of Signifor that requires twice-daily dosing is already approved to treat Cushing's disease, but was not considered commercially viable to treat acromegaly given the availability of rival depot formulations. (pmlive.com)
  • The aim of homeopathy is not only to treat acromegaly but to address its underlying cause and individual susceptibility. (hindustanlink.com)
  • As far as therapeutic medication is concerned, several remedies are available to treat acromegaly that can be selected on the basis of cause, sensations and modalities of the complaints. (hindustanlink.com)
  • An updated clinical practice guideline on acromegaly formulated by an expert task force jointly sponsored by the Endocrine Society and European Society of Endocrinology was recently released. (cns.org)
  • Although striking clinical features of acromegaly had been noticed for a long time, their association with hypersecretion of growth hormone (GH) was first suggested by Cushing. (springer.com)
  • Only nine years after the recognition of the features of acromegaly by Marie 1 in 1886, Huchard 2 reported cardiac enlargement in the clinical and autopsy findings of three patients with the disease. (annals.org)
  • 1987 Long term results of transsphenoidal surgery for the management of acromegaly. (pituitary.org)
  • Manifestations of acromegaly are varied and include acral and soft tissue overgrowth, joint pain, diabetes mellitus, hypertension, and heart and respiratory failure. (hindawi.com)
  • Excess GH stimulates increased hepatic secretion of insulin-like growth factor-1 (IGF-1), which causes most of the clinical manifestations of acromegaly, such as acral and soft tissue overgrowth in almost all adult patients. (gponline.com)
  • Dermatologic manifestations of acromegaly: A case in point and a focused review. (pubfacts.com)
  • [ 19 ] Medical therapies such as somatostatin analogs (SSAs), dopamine agonists, and the GH receptor antagonist have been widely studied in the management of patients with persistent or recurrent acromegaly after surgery and also may be used as an alternative to primary TSS. (medscape.com)
  • In 2017, Crinetics Pharmaceuticals, Inc. was awarded Phase IIB Small Business Innovation Research (SBIR) grant of up to US$ 2.8 million from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) for the development of company's orally-available, non-peptide somatostatin agonist drug candidate, CRN00808 that can be used for the treatment of acromegaly. (openpr.com)
  • For years, acromegaly has been managed using long-acting formulations of somatostatin analogues such as Novartis' own Sandostatin LAR (octreotide) and Ipsen's Somatuline Autogel (lanreotide), which are used to reduce levels of GH and IGF-1. (pmlive.com)
  • Medical Therapy with somatostatin analogs for acromegaly. (pituitary.org)
  • Basel , November 24, 2014 - Novartis announced today that the European Commission has approved Signifor ® (pasireotide) as a new long acting release formulation for once monthly intramuscular injection to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA). (novartis.com)
  • In a recent phase 3 trial, oral octreotide capsules demonstrated sustained biochemical response up to 13 months in patients with acromegaly previously managed with somatostatin analog injections (ref). (centerwatch.com)
  • Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. (springer.com)
  • Ching LJC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR. Long-term treatment of acromegaly with a long-acting analogue of somatostatin. (springer.com)
  • Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. (springer.com)
  • Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. (pubfacts.com)
  • OBJECTIVE The extent to which treatment modifies the excess in morbidity and mortality in acromegaly remains uncertain. (semanticscholar.org)
  • Control of GH hypersecretion lowers the morbidity and mortality associated with acromegaly. (pituitary.org)
  • In 2017, Midatech Pharma PLC submitted clinical trial application in human study of Q-Octreotide (MTD201) programme in cancer and acromegaly, and now it has received oral confirmation from Polish regulators for its approval in January 2018. (openpr.com)
  • The "US Acromegaly Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. (pharmiweb.com)
  • It is the most common cause of acromegaly. (wikidoc.org)
  • For instance, in December 2017, HealthWell Foundation launched a new fund scheme where it provided a fund of US$ 10,000 for a 12-month grant to acromegaly patients who have annual household incomes up to 400 percent of the federal poverty level. (openpr.com)
  • The global acromegaly market is expected to grow at a CAGR of ~5.2 % during the forecast period 2017-2023. (medgadget.com)